AB27620

Anti-VEGFA antibody [SP28], prediluted

RabMAb
Recombinant
Lab Essentials
What is this?

(2 Reviews)

(13 Publications)

Rabbit Recombinant Monoclonal VEGFA antibody. Suitable for IHC-P and reacts with Human samples. Cited in 13 publications.

View Alternative Names

VEGF, VEGFA, L-VEGF, Vascular permeability factor, VPF

2 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [SP28], prediluted (AB27620)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [SP28], prediluted (AB27620)

Immunohistochemical staining of human angiosarcoma labelling VEGF (SP28) with ab27620 at a 1 : 1 no dilution.

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [SP28], prediluted (AB27620)

Paraffin embedded formalin fixed human angioscarcoma tissue section stained with prediluted anti VEGF antibody ab27620.

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

SP28

Isotype

IgG

Carrier free

Reacts with

Human

Applications

IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/1", "IHCP-species-notes": "<p>Boil tissue section in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at room temperature for 20 min.</p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol." } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purity

Tissue culture supernatant

Storage buffer

pH: 7.6 Preservative: 0.1% Sodium azide Constituents: Tissue culture supernatant, Tris buffered saline, 1% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

+4°C

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Vascular endothelial growth factor A (VEGFA) also known as VEGF or vascular permeability factor (VPF) is a protein that plays a central role in angiogenesis as well as in the growth of blood vessels. The molecular weight of VEGFA varies depending on the isoform typically ranging from 34 to 42 kDa. VEGFA is expressed in many tissues including fibroblasts macrophages endothelial cells and platelets. Its expression levels can increase in response to stimuli like hypoxia or inflammatory cytokines. VEGFA is an important target in research for therapies related to vascular diseases and cancer.

Biological function summary

VEGFA functions by promoting the proliferation and migration of vascular endothelial cells. It operates both as a homodimer and as part of complex signaling cascades interacting with VEGF receptors on cell surfaces to trigger downstream signals for angiogenesis. This includes endothelial cell growth migration and the new blood vessel formation process. VEGFA's activity is important for physiological processes such as wound healing and embryonic development and it also contributes to pathological conditions through its unregulated expression in diseases.

Pathways

Many processes involve VEGFA including the PI3K/AKT pathway and the MAPK/ERK pathway. These pathways regulate cell survival growth and differentiation. Other proteins like PLGF (placenta growth factor) and VEGFB often accompany VEGFA in these pathways aiding in distinct but overlapping roles. These interactions are transmitted through binding to VEGF receptors such as VEGFR-1 and VEGFR-2 subsequently activating various signaling cascades necessary for cellular and tissue homeostasis.

VEGFA relates to cancer and age-related macular degeneration among others. In cancer overexpression of VEGFA can lead to excessive angiogenesis supplying blood to tumors and facilitating tumor growth. In age-related macular degeneration upregulation of VEGFA contributes to the progression of the disease by promoting the formation of abnormal blood vessels under the retina. Anti-VEGFA therapies such as anti-VEGF antibodies (e.g. bevacizumab) can target these overexpressed pathways. VEGFA interacts with other proteins like HIF-1α which regulates its expression under hypoxia a common condition in tumors.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

N-VEGF. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed : 35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity).. VEGFA. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed : 34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed : 17446437).. Isoform VEGF165B. Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.

See full target information VEGFA

style

left-column

Publications (13)

Recent publications for all applications. Explore the full list and refine your search

Bioactive materials 50:414-431 PubMed40309255

2025

Engineering fibroblast with reprogramming and spheronization for bone defect repair.

Applications

Unspecified application

Species

Unspecified reactive species

Yanjiao Li,Bin Jiang,Zhen Wu,Zhaoxia Ma,Lihua Qiu,Wen Cui,Yunhui Zhao,Jinghe Yan,Daiping Ma,Xingfei Wu,Shu Liang,Sitao Wang,Yanqun Zhao,Mengting Wang,Min Hu

Cancer diagnosis & prognosis 2:38-48 PubMed35400011

2022

Predictive Value of the Prognostic Nutritional Index in Neoadjuvant Chemoradiotherapy for Rectal Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Chika Mizutani,Nobuhisa Matsuhashi,Hiroyuki Tomita,Takao Takahashi,Tomonari Suetsugu,Jesse Yu Tajima,Shigeru Kiyama,Itaru Yasufuku,Yoshihiro Tanaka,Naoki Okumura,Katsutoshi Murase,Manabu Futamura,Masaya Kawaguchi,Takuma Ishihara,Masayuki Matsuo,Tatsuhiko Miyazaki,Akira Hara,Kazuhiro Yoshida

Orbit (Amsterdam, Netherlands) 40:120-126 PubMed32264727

2020

Accelerated growth of orbital schwannomas during pregnancy does not correlate with sex hormone- or growth factor receptor status.

Applications

Unspecified application

Species

Unspecified reactive species

G J Hötte,N Meijer,R M Verdijk,D Paridaens

Thoracic cancer 11:1258-1264 PubMed32163231

2020

The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yuji Shibata,Nobuaki Kobayashi,Takashi Sato,Kentaro Nakashima,Takeshi Kaneko

EMBO molecular medicine 10: PubMed29930174

2018

A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.

Applications

Unspecified application

Species

Unspecified reactive species

Daniel E Foxler,Katherine S Bridge,John G Foster,Paul Grevitt,Sean Curry,Kunal M Shah,Kathryn M Davidson,Ai Nagano,Emanuela Gadaleta,Hefin I Rhys,Paul T Kennedy,Miguel A Hermida,Ting-Yu Chang,Peter E Shaw,Louise E Reynolds,Tristan R McKay,Hsei-Wei Wang,Paulo S Ribeiro,Michael J Plevin,Dimitris Lagos,Nicholas R Lemoine,Prabhakar Rajan,Trevor A Graham,Claude Chelala,Kairbaan M Hodivala-Dilke,Ian Spendlove,Tyson V Sharp

Frontiers in neurology 9:272 PubMed29755400

2018

Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Isaac Almendros,Miguel Ángel Martínez-García,Francisco Campos-Rodríguez,Erica Riveiro-Falkenbach,José L Rodríguez-Peralto,Eduardo Nagore,Antonio Martorell-Calatayud,Luis Hernández Blasco,Jose Bañuls Roca,Eusebi Chiner Vives,Alicia Sánchez-de-la-Torre,Jorge Abad-Capa,Josep Maria Montserrat,Amalia Pérez-Gil,Valentín Cabriada-Nuño,Irene Cano-Pumarega,Jaime Corral-Peñafiel,Trinidad Diaz-Cambriles,Olga Mediano,Joan Dalmau-Arias,Ramon Farré,David Gozal

The journal of pathology. Clinical research 4:184-192 PubMed29654716

2018

Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.

Applications

Unspecified application

Species

Unspecified reactive species

Anthoula Lazaris,Abdellatif Amri,Stephanie K Petrillo,Paublo Zoroquiain,Nisreen Ibrahim,Ayat Salman,Zu-Hua Gao,Peter B Vermeulen,Peter Metrakos

The European respiratory journal 51: PubMed29519923

2018

Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea.

Applications

Unspecified application

Species

Unspecified reactive species

Fernando Santamaria-Martos,Ivan Benítez,Cristina Girón,Ferran Barbé,Miguel-Angel Martínez-García,Luis Hernández,Josep M Montserrat,Eduardo Nagore,Antonio Martorell,Francisco Campos-Rodriguez,Jaime Corral,Valentin Cabriada,Jorge Abad,Olga Mediano,Maria F Troncoso,Irene Cano-Pumarega,Ana Maria Fortuna Gutierrez,Trinidad Diaz-Cambriles,Maria Somoza-Gonzalez,Isaac Almendros,Ramon Farre,David Gozal,Manuel Sánchez-de-la-Torre

Journal of ovarian research 11:18 PubMed29490689

2018

Metformin improves ovarian follicle dynamics by reducing theca cell proliferation and CYP-17 expression in an androgenized rat model.

Applications

Unspecified application

Species

Unspecified reactive species

Roberta Rassi Mahamed,Carla Cristina Maganhin,Gisela Rodrigues Silva Sasso,Manuel de Jesus Simões,Maria Candida Pinheiro Baracat,Edmund Chada Baracat,José Maria Soares-

BMC cancer 12:570 PubMed23206236

2012

Pyloric gland adenoma of the cystic duct with malignant transformation: report of a case with a review of the literature.

Applications

Unspecified application

Species

Human

Inga-Marie Schaefer,Silke Cameron,Peter Middel,Kia Homayounfar,Harald Schwörer,Michael Vieth,Lothar Veits

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-VEGFA antibody [SP28], prediluted

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [SP28], prediluted (AB27620)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [SP28], prediluted (AB27620)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Properties and storage information

Form

Purity

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (13)

Product promise